Effects of Seated Exercise on Fatigue Associated With Prolonged Sitting During High-Speed Rail Travel
NCT07922603, Not applicable, Completed, Aiyoudong Children and Youth Sports Health Research Institute
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Seated Exercise on Fatigue Associated With Prolonged Sitting During High-Speed Rail Travel | ClinicalTrials.gov |
| NCT number | NCT07922603 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 120 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Aiyoudong Children and Youth Sports Health Research Institute | ClinicalTrials.gov |
| Conditions | Sedentary Behavior, Fatigue, Prolonged Sitting | ClinicalTrials.gov |
| Interventions | Standardized Age-Specific Seated Exercise Program, Prolonged Sitting Control | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-06 | ClinicalTrials.gov |
Registered outcomes 13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Subjective Fatigue | Baseline (T0), immediately after the initial intervention (T1), and at the end of the approximately 7-hour sitting session (T2) | Subjective fatigue will be assessed using an age-appropriate Visual Analog Scale (VAS). Participants aged 7-18 years will use an age-adapted visual scale, while adult participants will use a standard VAS. Scores will be standardized to a 0-100 scale for analysis, with higher scores indicating greater subjective fatigue. | ClinicalTrials.gov |
| Secondary | Change in Subjective Sleepiness | Baseline (T0), immediately after the initial intervention (T1), and at the end of the approximately 7-hour sitting session (T2) | Subjective sleepiness will be assessed using the Karolinska Sleepiness Scale (KSS) or an age-adapted version for younger participants. Higher scores indicate greater sleepiness. | ClinicalTrials.gov |
| Secondary | Change in Local Musculoskeletal Discomfort | Baseline (T0), immediately after the initial intervention (T1), and at the end of the approximately 7-hour sitting session (T2) | Local musculoskeletal discomfort will be assessed using a numerical rating scale or an age-appropriate facial rating scale. Higher scores indicate greater perceived discomfort or pain. | ClinicalTrials.gov |
| Secondary | Change in Positive and Negative Affect | Baseline (T0), immediately after the initial intervention (T1), and at the end of the approximately 7-hour sitting session (T2) | Mood will be assessed using the Positive and Negative Affect Schedule (PANAS) or an age-adapted version for younger participants. Positive and negative affect scores will be analyzed separately. | ClinicalTrials.gov |
| Secondary | Change in Psychomotor Vigilance | Baseline (T0) and at the end of the approximately 7-hour sitting session (T2) | Psychomotor vigilance will be assessed using a 3-minute Psychomotor Vigilance Task (PVT). Outcomes will include reaction time and lapses, with longer reaction times and more lapses indicating poorer vigilance. | ClinicalTrials.gov |
| Secondary | Change in Working Memory Performance | Baseline (T0) and at the end of the approximately 7-hour sitting session (T2) | Working memory will be assessed using an n-back task. Accuracy and reaction time will be recorded. Age-appropriate task difficulty will be used for younger participants. | ClinicalTrials.gov |
| Secondary | Change in Inhibitory Control Performance | Baseline (T0) and at the end of the approximately 7-hour sitting session (T2) | Inhibitory control will be assessed using a Stroop task. Accuracy, reaction time, and interference-related performance will be recorded using age-appropriate task versions. | ClinicalTrials.gov |
| Secondary | Change in Heart Rate Variability | Baseline (T0) and at the end of the approximately 7-hour sitting session (T2) | Autonomic nervous system function will be assessed using heart rate variability (HRV). Primary HRV indices will include RMSSD and SDNN. | ClinicalTrials.gov |
| Secondary | Change in Salivary Cortisol Concentration | Baseline (T0) and at the end of the approximately 7-hour sitting session (T2) | Salivary cortisol concentration will be measured as an indicator of physiological stress response. | ClinicalTrials.gov |
| Secondary | Change in Salivary Alpha-Amylase Activity | Baseline (T0) and at the end of the approximately 7-hour sitting session (T2) | Salivary alpha-amylase activity will be measured as an additional biomarker of physiological stress and autonomic activation. | ClinicalTrials.gov |
| Secondary | Change in Plantar Pressure and Postural Control | Baseline (T0) and at the end of the approximately 7-hour sitting session (T2) | Plantar pressure and postural control will be assessed using a plantar pressure platform. Outcomes will include plantar pressure distribution and center-of-pressure measures such as path length and mean velocity. | ClinicalTrials.gov |
| Secondary | Change in Surface Electromyographic Indicators of Muscle Fatigue | Baseline (T0) and at the end of the approximately 7-hour sitting session (T2) | Surface electromyography (sEMG) will be used to assess neuromuscular changes associated with prolonged sitting. Amplitude- and frequency-domain indicators of muscle activity and fatigue will be analyzed. | ClinicalTrials.gov |
| Secondary | Change in Electroencephalographic Spectral Power | Baseline (T0) and at the end of the approximately 7-hour sitting session (T2) | Electroencephalography (EEG) will be used to assess neurophysiological changes associated with prolonged sitting and seated exercise. Spectral power in the theta, alpha, and beta frequency bands will be analyzed. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| 1-Back Task | Secondary outcome | ConductCognition |
| 2-Back Task | Secondary outcome | ConductCognition |
| Psychomotor Vigilance Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)